<DOC>
	<DOCNO>NCT00773968</DOCNO>
	<brief_summary>This single arm study ass long term maintenance hemoglobin ( Hb ) level , safety tolerability monthly subcutaneous methoxy polyethylene glycol-epoetin beta ( CERA ) predialysis participant chronic renal anemia . Participants currently receive subcutaneous darbopoetin alfa maintenance treatment receive subcutaneous methoxy polyethylene glycol-epoetin beta maximum 32 week start dose 120 , 200 360 microgram every 4 week accord dose darbopoetin alfa administer Week -1 . Subsequent dos adjust maintain hemoglobin level within target range 10 12 gram per deciliter ( g/dL ) .</brief_summary>
	<brief_title>A Study Monthly Subcutaneous Continuous Erythropoietin Receptor Activator ( CERA ) Predialysis Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic renal anemia ; Continuous subcutaneous maintenance darbopoetin alfa treatment previous month ; Hb concentration 10 12 g/dL ; Adequate iron status . Transfusion red blood cell previous 2 month ; Significant acute chronic bleeding , overt gastrointestinal bleeding ; Poorly control hypertension require hospitalization interruption darbopoetin alfa treatment previous 6 month ; Active malignant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>